News Category: Press Release
-
Scripps Research team pioneers an efficient way to stereoselectively add fluorine to drug-like molecules
A new method uses a novel catalyst and inexpensive fluoride salts to modify the most common chemical bonds—opening doors to new medicines and improved medical imaging.
-
An easier approach to recreate the powerful nerve-blocking molecule found in shellfish
A Scripps Research-led study resolves the challenge of synthesizing saxitoxin, paving the way for new possibilities in pain management.
-
Scientists find cancer weak spot in backup DNA repair system
New findings from Scripps Research reveal how certain tumors survive DNA damage—and point to a strategy for targeting them.
-
Scripps Research scientists receive $1.1 million to advance AI modeling for HIV vaccine development
New AI system helps scientists rapidly pinpoint the most promising paths to an HIV vaccine.
-
Scripps Research study reveals how uterine contractions are regulated by stretch and pressure during childbirth
Molecular insights could lead to improved labor and pain treatments.
-
Scripps Research scientists honored on Clarivate’s Highly Cited Researchers list
The recognized researchers encompass various areas including chemistry, microbiology, immunology, biochemistry and more.
-
Scripps Research team identifies sugar molecules that trigger placental formation
Study reveals how sugar-protein interactions are critical for the placenta during early pregnancy, shedding light on complications like preeclampsia and restricted fetal growth.
-
Douglas W. Phillips and Steven M. Paul join Scripps Research Board of Directors
Finance and biomedical leaders bring decades of experience in investment strategy and drug development.
-
Scripps Research awarded $6.9 million by NIH to crack the code of lasting HIV vaccine protection
The funding will support a multidisciplinary collaboration of four Scripps Research scientists to identify more effective vaccines to treat HIV.
-
Scripps Research scientists launch new digital clinical trial to test repurposed drug for long COVID symptom relief
Study will investigate whether a GIP/GLP-1 dual receptor agonist, currently approved for type 2 diabetes, obesity and obstructive sleep apnea, can reduce symptoms of long COVID.